Edison Oncology Holding, a Phase 2 biotech developing targeted small-molecule oncology therapies, withdrew its plans for an initial public offering on Friday. It had filed to raise $25 million by offering 2.8 million shares (2% secondary) at a price range of $8 to $10.
The Menlo Park, CA-based company was founded in 2018 and had planned to list on the NYSE American under the symbol EOHC. Konik Capital Partners was set to be the sole bookrunner on the deal.
